Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital praises AB Foods' actions to turn business around

(Sharecast News) - Shore Capital has reiterated a 'buy' rating for retail and food conglomerate Associated British Foods, praising the company's recent actions to deal with underperforming parts of the business. Ahead of a trading update expected from the firm in September, the broker noted ABF's "demonstrable action to deal with persistent problem children" - namely its bioethanol business Vivergo, the Spanish sugar division Azucarera and UK bakery operations Allied.

The company has already announced that has kickstarted a restructuring of Azucarera, which involves simplifying its manufacturing operations, cutting costs and improving efficiency. Meanwhile, it is currently negotiating with the UK government about Vivergo to find a regulatory solution that it hopes will mitigate certain rules on imported ethanol and the impact of US trade tariffs.

Meanwhile, ABF announced on Friday that it was acquiring the Hovis Brand in an effort to bolster the Allied division, bringing together "two of the leading names in the UK sliced bread market", according to Shore Capital.

"Quite how much profitability will emerge and when, remains to be seen, but we can foresee a welcome boost to ABF's Grocery division here, given that Allied has been making trading losses amounting to, we suspect, £20-30m per annum for some time," the broker said.

Shore Capital said it "applauded these workstreams", adding: "Aligning the stars of ABF is virtuous to the group's investment thesis, to us, and so bringing Allied, Azucarera and Vivergo in from the cold is welcome news.

"In the big scheme of things, [...] we welcome the important improvement in prospects for its UK bakery division, and we reiterate our Buy stance on ABF equity where valuation multiples remain undemanding, to us."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.